<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687219</url>
  </required_header>
  <id_info>
    <org_study_id>P05116</org_study_id>
    <secondary_id>JPC-06-320-35</secondary_id>
    <nct_id>NCT00687219</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)</brief_title>
  <official_title>Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of combination therapy with
      peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks
      in participants with chronic hepatitis C and type C compensated liver cirrhosis. Participants
      who are hepatitis C virus ribonucleic acid (HCV-RNA) positive after 24 weeks of treatment
      will be discontinued from therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)</measure>
    <time_frame>Measured at 24 weeks after 48 weeks treatment (72 weeks)</time_frame>
    <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Undetectable HCV-RNA at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Undetectable HCV-RNA at End of Treatment</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2b + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>Administered at 1.0 µg/kg/week SC for 48 weeks</description>
    <arm_group_label>Peginterferon alfa-2b + Ribavirin</arm_group_label>
    <other_name>SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL; treatment duration is 48 weeks</description>
    <arm_group_label>Peginterferon alfa-2b + Ribavirin</arm_group_label>
    <other_name>SCH 018908</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 20-70 years.

          -  Positive quantitative serum HCV-RNA.

          -  Participants classified as A in Child-Pugh classification, and who do not have ascites
             or hepatic encephalopathy.

          -  Diagnosed with type C compensated liver cirrhosis based on liver biopsy performed
             within 3 years or latest celioscopy.

          -  Prolonged prothrombin time by &lt;=3.0 sec.

          -  Participants and partners of participants willing to use adequate contraception during
             the course of the study.

          -  Participants who can be hospitalized for at least 14 days since treatment initiation.

          -  Weight &gt;40 kg and &lt;=100 kg

          -  Hematology laboratory results of:

               -  hemoglobin &gt;=12 g/dL

               -  neutrophil count &gt;=1,500/mm^3

               -  platelet count &gt;=70,000/ mm^3

          -  Blood chemistry results of:

               -  albumin and direct bilirubin within normal limits

               -  alpha fetoprotein (AFP) within reference range

               -  AFP-L3&lt;=10%

               -  Protein induced by vitamin K (PIVKA)-II &lt;=100 mAU/mL

        Exclusion Criteria:

          -  Participants who did not previously respond virologically to combination therapy with
             interferon (including polyethylene glycol-modified interferon) and ribavirin

          -  Participants who had previously received treatment with interferon for whom at least
             90 days have not elapsed since the end of previous treatment

          -  Participants who have received treatment within 14 days prior to registration with
             injectable preparations containing glycyrrhizin/cysteine/glycyron or shosaikoto

          -  Participants who have received administration of drugs having antiviral, anti-tumor,
             or immuno-modulating effect (including glucocorticoids and radiation therapy) within
             90 days prior to registration (excluding local administration and topicals)

          -  Participants who have received other investigational drugs within 180 days prior to
             registration

          -  Hepatitis B surface (HBs) antigen positive

          -  Antinuclear antibody &gt;=320 times

          -  Serum creatinine exceeding the upper limit of reference range

          -  Participants with fasting blood glucose &gt;=110 mg/dL (participants with fasting blood
             glucose &gt;=110 mg/dL and &lt;126 mg/dL can be registered if their hemoglobin A1C (HbA1c)
             is &lt;6.5%) [fasting blood glucose should be measured when participants are not
             receiving treatment for diabetes mellitus]

          -  Participants with any of the following: diabetes mellitus that requires treatment;
             thyroid function disorder not controlled by treatment; liver disease such as
             autoimmune, alcoholic and drug-induced liver diseases; hemophilia; arrhythmia
             requiring treatment; co-existing hypertension not controlled by drug therapy (systolic
             blood pressure [BP] &gt;=160mmHg or diastolic BP&gt;=100mmHg); chronic pulmonary disease;
             hemoglobinopathies (thalassemia, sickle cell anemia); malignant tumors or who have a
             history of malignant tumor within the past 5 years; organ transplants (other than
             cornea and hair transplant)

          -  Participants with or who have a history of primary biliary cirrhosis, liver failure,
             hepatic carcinoma; decompensated liver cirrhosis with any the following diseases:
             ascites, jaundice, variceal hemorrhage, esophageal or gastric varices requiring
             treatment, hepatic encephalopathy, and idiopathic bacterial peritonitis; depression or
             schizophrenia requiring treatment, or suicidal attempt or suicidal ideation; epileptic
             seizures requiring treatment; angina, cardiac failure, myocardial infarction, or
             life-threatening arrhythmia; autoimmune disease (Hashimoto's disease, Crohn's disease,
             ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura,
             systemic erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); hepatic
             carcinoma

          -  Participants with a history of hypersensitivity to interferon preparations, biological
             products such as vaccine, or nucleoside analogs, and those with specific reaction to
             pegylated interferon alfa-2b in the prick test conducted before the initiation of
             treatment

          -  Women who are pregnant or nursing as well as women for whom pregnancy cannot be ruled
             out by serum human chorionic gonadotropin (HCG) test conducted during the screening
             period. Male participants with partners who are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>October 27, 2011</results_first_submitted>
  <results_first_submitted_qc>October 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2011</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon Alfa-2b + Ribavirin</title>
          <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuance criteria met</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HCV-RNA positive conversion</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon Alfa-2b + Ribavirin</title>
          <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)</title>
        <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
        <time_frame>Measured at 24 weeks after 48 weeks treatment (72 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2b + Ribavirin</title>
            <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)</title>
          <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undetectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (data not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Undetectable HCV-RNA at Week 24</title>
        <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
        <time_frame>Week 24</time_frame>
        <population>Peginterferon alfa-2b administered at 1.0 μg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2b + Ribavirin</title>
            <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV-RNA at Week 24</title>
          <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
          <population>Peginterferon alfa-2b administered at 1.0 μg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undetectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (data not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Undetectable HCV-RNA at End of Treatment</title>
        <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
        <time_frame>Up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2b + Ribavirin</title>
            <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV-RNA at End of Treatment</title>
          <description>Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undetectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable HCV-RNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (data not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon Alfa-2b + Ribavirin</title>
          <description>Peginterferon alfa-2b administered at 1.0 µg/kg/week SC for 48 weeks plus ribavirin administered based on body weight and hemoglobin value at screening: 600-1000 mg/day
for subjects with hemoglobin value at screening &gt;=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening &gt;=12g/dL and &lt;14g/dL for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="48" subjects_affected="37" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="47" subjects_affected="43" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PRURITUS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="103" subjects_affected="90" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="122" subjects_affected="96" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="54" subjects_affected="36" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BASOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD ALBUMIN DECREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD AMYLASE INCREASED</sub_title>
                <counts group_id="E1" events="44" subjects_affected="33" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN UNCONJUGATED INCREASED</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD CHLORIDE INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE DECREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" events="39" subjects_affected="32" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>EOSINOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>GLYCOSYLATED HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" events="87" subjects_affected="82" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="94" subjects_affected="91" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>HYALURONIC ACID INCREASED</sub_title>
                <counts group_id="E1" events="59" subjects_affected="52" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="107" subjects_affected="89" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" events="45" subjects_affected="32" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="113" subjects_affected="87" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="76" subjects_affected="65" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="88" subjects_affected="86" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RETICULOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RETICULOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RETICULOCYTE PERCENTAGE DECREASED</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RETICULOCYTE PERCENTAGE INCREASED</sub_title>
                <counts group_id="E1" events="62" subjects_affected="56" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>THYROXINE FREE DECREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>TRI-IODOTHYRONINE FREE DECREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="108" subjects_affected="94" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="77" subjects_affected="61" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="70" subjects_affected="56" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="70" subjects_affected="56" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="111" subjects_affected="83" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="52" subjects_affected="45" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>MOOD ALTERED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

